NCT04481009View on ClinicalTrials.gov

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

May 16, 2022

Study Completion Date

May 26, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

YH003

YH003 will be administered intravenously over 60 minutes every 21-day cycle.

DRUG

Toripalimab

Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered each 21-day cycle.

DRUG

Gemcitabine

Gemcitabine will be administrated each 21-day cycle.

Trial Locations (1)

6009

Linear Clinical Research, Nedlands

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY

NCT04481009 - A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter